专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明专利

CA2285922C METHODS OF DIAGNOSING CLINICAL SUBTYPES OF CROHN'S DISEASE WITH CHARACTERISTIC RESPONSIVENESS TO ANTI-TH1 CYTOKINE THERAPY 未知
公开(公告)号：CA2285922C
公开(公告)日：2008-07-29
申请号：CA2285922
申请日：1998-04-08
申请人： PROMETHEUS LAB INC , CEDARS SINAI MEDICAL CENTER
发明人： TARGAN STEPHAN R , BARRY MARY J , TAYLOR KENT , PLEVY SCOTT E
IPC分类号： C12Q1/68 , C07K14/525 , C12N15/28 , G01N33/543 , G01N33/564 , G01N33/68
摘要： The present invention provides methods based on serological and genetic markers for diagnosing clinical subtypes of Crohn's disease (CD) having characteristic responsiveness to anti-Th1 cytokine therapy. In the methods of the invention, the presence of perinuclear anti-neutrophil antibody (pANCA), the presence of the TNFa10b4c1d3e3 haplotype or the presence of TNFa11b4c1d3e3 haplotype each is independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. In addition, the presence of the homozygous TNF-.beta. 1111 haplotype involving the TNFc, aa13L, aa26 and NcoI loci is independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. The presence of speckling anti-pan polymorphonuclear antibody (SAPPA) is diagnostic of a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy.

52. 发明专利

CA2286392C METHODS OF DIAGNOSING A MEDICALLY RESISTANT CLINICAL SUBTYPE OF ULCERATIVE COLITIS 未知
公开(公告)号：CA2286392C
公开(公告)日：2008-04-08
申请号：CA2286392
申请日：1998-04-09
申请人： CEDARS SINAI MEDICAL CENTER
发明人： TARGAN STEPHAN R , PLEVY SCOTT E
IPC分类号： G01N33/569 , C12Q1/68 , G01N33/53 , G01N33/68
摘要： The present invention provides serological and genetic methods of diagnosing a medically resistant clinical subtype of ulcerative colitis UC. The present invention provides a method of diagnosing a medically resistanc clinical subtype of UC by determining the presence or absence of anti-Saccharomyces cerevisiae antibodies (ASCA) in a patient with UC, where the presence of ASCA indicates the medically resistant clinical subtype of UC. The present invention also provides a method of diagnosing a medically resistant clinical subtype of UC by determining the presence or absence of a TNFa2b1c2d4e1 haplotype in a patient with UC, where the presence of said TNFa2b1c2d4e1 haplotype indicates the medically resistant clinical subtype of UC. In addition, the invention provides a method of disgnosing a medically resistant clinical subtype of UC by determining the presence or absence of a TNFa2b1c2d4e1 haplotype in a patient with UC and determining the presence or absence of ASCA in the patient with UC, where the presence of said TNFa2b1c2d4e1 haplotype indicates the medically resistant clinical subtype of UC and the presence of ASCA independently indicates the medially resistant clinical subtype of UC. The invention further provides kits for diagnosing a medical resistant clinical subtype of UC containing antigen specific for ASCA and one or more oligonucleotide primers complementary to a nucleotide suquence flanking TNF microsatellite locus TNFa, TNFb, TNFc, TNFd or TNFe.

53. 发明专利

ES2166822T3 未知
公开(公告)号：ES2166822T3
公开(公告)日：2002-05-01
申请号：ES95921264
申请日：1995-05-17
申请人： CEDARS SINAI MEDICAL CENTER
发明人： PLEVY SCOTT E , ROTTER JEROME I , TARGAN STEPHAN R , TOYODA HIROO , YANG HUIYING
IPC分类号： C12Q1/68 , C12Q1/6858 , C12Q1/6883 , C07H21/04 , C12P19/34
摘要： A novel association between certain tumor necrosis factor microsatellite alleles and Crohn's disease has been discovered. In accordance with the present invention, there is provided methods for screening for Crohn's disease comprising detecting the presence or absence of nucleic acid of a subject encoding TNF microsatellite alleles associated with Crohn's disease, wherein the presence of nucleic acid encoding three or more of the alleles is indicative of Crohn's disease. Kits useful for screening for Crohn's disease are also provided which comprise nucleic acid encoding TNF microsatellite alleles associated with Crohn's disease.

54. 发明专利

AU6957498A Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-th1 cytokine therapy 未知
公开(公告)号：AU6957498A
公开(公告)日：1998-11-11
申请号：AU6957498
申请日：1998-04-08
申请人： CEDARS SINAI MEDICAL CENTER , PROMETHEUS LABORATORIES INC
发明人： PLEVY SCOTT E , TARGAN STEPHAN R , TAYLOR KENT , BARRY MARY J
IPC分类号： C07K14/525 , G01N33/564 , G01N33/68 , C12P19/34

55. 发明专利

AU6956298A Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis 未知
公开(公告)号：AU6956298A
公开(公告)日：1998-11-11
申请号：AU6956298
申请日：1998-04-09
申请人： CEDARS SINAI MEDICAL CENTER
发明人： PLEVY SCOTT E , TARGAN STEPHAN R
IPC分类号： C12Q1/68 , G01N33/569 , G01N33/68 , G01N33/53
摘要： The present invention provides serological and genetic methods of diagnosing a medically resistant clinical subtype of ulcerative colitis UC. The present invention provides a method of diagnosing a medically resistant clinical subtype of UC by determining the presence or absence of anti-Saccharomyces cerevisiae antibodies (ASCA) in a patient with UC, where the presence of ASCA indicates the medically resistant clinical subtype of UC. The present invention also provides a method of diagnosing a medically resistant clinical subtype of UC by determining the presence or absence of a TNFa2b1c2d4e1 haplotype in a patient with UC, where the presence of said TNFa2b1c2d4e1 haplotype indicates the medically resistant clinical subtype of UC. In addition, the invention provides a method of diagnosing a medically resistant clinical subtype of UC by determining the presence or absence of a TNFa2b1c2d4e1 haplotype in a patient with UC and determining the presence or absence of ASCA in the patient with UC, where the presence of said TNFa2b1c2d4e1 haplotype indicates the medically resistant clinical subtype of UC and the presence of ASCA independently indicates the medically resistant clinical subtype of UC. The invention further provides kits for diagnosing a medically resistant clinical subtype of UC containing antigen specific for ASCA and one or more oligonucleotide primers complementary to a nucleotide sequence flanking TNF microsatellite locus TNFa, TNFb, TNFc, TNFd or TNFe.

56. 发明专利

CA2286392A1 METHODS OF DIAGNOSING A MEDICALLY RESISTANT CLINICAL SUBTYPE OF ULCERATIVE COLITIS 未知
公开(公告)号：CA2286392A1
公开(公告)日：1998-10-22
申请号：CA2286392
申请日：1998-04-09
申请人： CEDARS SINAI MEDICAL CENTER
发明人： PLEVY SCOTT E , TARGAN STEPHAN R
IPC分类号： C12Q1/68 , G01N33/569 , G01N33/68 , G01N33/53
摘要： The present invention provides serological and genetic methods of diagnosing a medically resistant clinical subtype of ulcerative colitis UC. The present invention provides a method of diagnosing a medically resistanc clinical subtype of UC by determining the presence or absence of anti-Saccharomyces cerevisiae antibodies (ASCA) in a patient with UC, where the presence of ASCA indicates the medically resistant clinical subtype of UC. The present invention also provides a method of diagnosing a medically resistant clinical subtype of UC by determining the presence or absence of a TNFa2b1c2d4e1 haplotype in a patient with UC, where the presence of said TNFa2b1c2d4e1 haplotype indicates the medically resistant clinical subtype of UC. In addition, the invention provides a method of disgnosing a medically resistant clinical subtype of UC by determining the presence or absence of a TNFa2b1c2d4e1 haplotype in a patient with UC and determining the presence or absence of ASCA in the patient with UC, where the presence of said TNFa2b1c2d4e1 haplotype indicates the medically resistant clinical subtype of UC and the presence of ASCA independently indicates the medially resistant clinical subtype of UC. The invention further provides kits for diagnosing a medical resistant clinical subtype of UC containing antigen specific for ASCA and one or more oligonucleotide primers complementary to a nucleotide suquence flanking TNF microsatellite locus TNFa, TNFb, TNFc, TNFd or TNFe.

57. 发明专利

CA2285922A1 METHODS OF DIAGNOSING CLINICAL SUBTYPES OF CROHN'S DISEASE WITH CHARACTERISTIC RESPONSIVENESS TO ANTI-TH1 CYTOKINE THERAPY 未知
公开(公告)号：CA2285922A1
公开(公告)日：1998-10-22
申请号：CA2285922
申请日：1998-04-08
申请人： CEDARS SINAI MEDICAL CENTER , PROMETHEUS LAB INC
发明人： TARGAN STEPHAN R , TAYLOR KENT , BARRY MARY J , PLEVY SCOTT E
IPC分类号： C07K14/525 , G01N33/564 , G01N33/68 , G01N33/543 , C12Q1/68 , G01N33/74
摘要： The present invention provides methods based on serological and genetic markers for diagnosing clinical subtypes of Crohn's disease (CD) having characteristic responsiveness to anti-Th1 cytokine therapy. In the methods of the invention, the presence of perinuclear anti-neutrophil antibody (pANCA), the presence of the TNFa10b4c1d3e3 haplotype or the presence of TNFa11b4c1d3e3 haplotype each is independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. In addition, the presence of the homozygous TNF-.beta. 1111 haplotype involving the TNFc, aa13L, aa26 and NcoI loci is independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. The presence of speckling anti-pan polymorphonuclear antibody (SAPPA) is diagnostic of a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy.

58. 发明专利

CA2223439A1 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY MATERIAL ASSOCIATED WITH ULCERATIVE COLITIS AND RELATED METHODS AND KITS 未知
公开(公告)号：CA2223439A1
公开(公告)日：1996-12-12
申请号：CA2223439
申请日：1996-06-05
申请人： CEDARS SINAI MEDICAL CENTER , UNIV CALIFORNIA
发明人： TARGAN STEPHAN R , EGGENA MARK P , BRAUN JONATHAN
IPC分类号： C12N15/09 , A61K39/395 , A61P1/04 , C07K16/18 , C12P21/08 , G01N33/53 , G01N33/569 , G01N33/68 , C12N15/13 , C07K1/22 , C07K14/47 , C07K16/42 , C12N7/01 , G01N33/564
摘要： For the first time, the present invention provides isolated, substantially pure, and/or recombinantly produced pANCA associated with ulcerative colitis (UCpANCA and UCpANCA material) as well as polynucleotides encoding the UCpANCA, UCpANCA material and UCpANCA polypeptides of the present invention. Using the phage display technique, immunoglobulin gene repertoires biased for the immunoglobulin genes utilized by pANCA seropositive UC patients have been isolated, amplified, randomly re-combined to generate phagemid expression vector libraries encoding DNA homologs of the gene repertoire. Methods are provided for enriching these libraries to create libraries of VH- and VLencoding DNA homologs having immunoreactivity of UCpANCA antigen. Also provided are methods of screening the libraries of the present invention for UCpANCA and UCpANCA material. These libraries may be encapsulated in phage particles or in cells. Methods and kits are also provided for screening for UCpANCA in a sample and isolating UCpANCA antigen.

59. 发明专利

CA2190586A1 METHODS OF SCREENING FOR CROHN'S DISEASE USING TNF MICROSATELLITE ALLELES 未知
公开(公告)号：CA2190586A1
公开(公告)日：1995-11-23
申请号：CA2190586
申请日：1995-05-17
申请人： CEDARS SINAI MEDICAL CENTER
发明人： PLEVY SCOTT E , ROTTER JEROME I , TARGAN STEPHAN R , TOYODA HIROO , YANG HUIYING
IPC分类号： C12Q1/68 , C12Q1/6858 , C12Q1/6883 , C07H21/00
摘要： A novel association between certain tumor necrosis factor microsatellite alleles and Crohn's disease has been discovered. In accordance with the present invention, there is provided methods for screening for Crohn's disease comprising detecting the presence or absence of nucleic acid of a subject encoding TNF microsatellite alleles associated with Crohn's disease, wherein the presence of nucleic acid encoding three or more of the alleles is indicative of Crohn's disease. Kits useful for screening for Crohn's disease are also provided which comprise nucleic acid encoding TNF microsatellite alleles associated with Crohn's disease.

60. 发明专利

CA2978616A1 METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH IFN-GAMMA THERAPY 未知
公开(公告)号：CA2978616A1
公开(公告)日：2016-09-22
申请号：CA2978616
申请日：2016-03-15
申请人： CEDARS-SINAI MEDICAL CENTER
发明人： TARGAN STEPHAN R , BILSBOROUGH JANINE , MCGOVERN DERMOT P
IPC分类号： A61K39/395 , A61P35/00 , C07K16/24
摘要： The present invention describes methods for treating inflammatory disorders of the gastrointestinal tract, including but not limited to Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC) and/or medically refractory ulcerative colitis (MR-UC) using anti-IFNG therapy. The present invention also describes a process for patient risk stratification.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式